Spotlight on Internal Medicine

Credits: 0.50 CME / CNE
ADPKD - What Your Patients Want You to Know
Brittany Cavanaugh, DO
Global Education Group

ADPKD - What Your Patients Want You to Know

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: December 31, 2018
Expires: December 31, 2019
30 minutes to complete

Jointly Provided By

In Partnership With

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Terms of Offering

This activity was released on 12/31/18 and is valid for one year. Requests for credit must be made no later than 12/31/19.

Target Audience

The educational design of this activity addresses the needs of nephrology and primacy care HCPs involved in the treatment of patients with ADPKD.

Statement of Need/Program Overview

Autosomal dominant polycystic kidney disease (ADPKD) is a chronic inherited progressive condition in which renal cysts develop and expand, eventually leading to severe loss of kidney function. Complications include pain, hypertension, and cardiovascular disease. Unless patients undergo dialysis or transplantation, ADPKD is inevitably fatal. Because it is a genetically transmitted disease, there is a 50/50 chance that each child of a parent with ADPKD will develop the disease. Management of ADPKD has evolved significantly in recent years; in 2018, the first drug indicated for slowing progression of the disease was approved.

ADPKD is considered a rare disease, but with a prevalence of approximately 1:1000, the odds are high that most primary care practices have 1 or more patients with the condition – whether or not it has been diagnosed. Primary care providers would benefit from education that raises their awareness of ADPKD, explains strategies for managing the disease and its complications, and provides them with tools to promote and preserve optimal patient health for as long as possible.

This unique online Clinical Comparison CME/CE activity allows learners to learn about ADPKD, discover evidence-based treatment strategies, apply their learning in a series of interactive real-world challenges, receive feedback on their choices, and compare their choices with those of their peers. The content of the program was developed, in part, through interviews with ADPKD patients and their caregivers, who shared their insights and what they wish their clinicians knew about the disease, its management, and its impact on their lives.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Identify clinical approaches for the early recognition, efficient evaluation, and timely diagnosis of autosomal dominant polycystic kidney disease (ADPKD)
  • Identify data-driven approaches to the comprehensive care of patients with ADPKD
  • Recognize which patients with ADPKD are most likely to benefit from currently available and emerging therapies for ADPKD

Faculty

Brittany P. Cavanaugh, DO
Professor of Internal Medicine
Yale University School of Medicine
New Haven, Connecticut


Neera Dahl, MD
Associate Professor of Nephrology
Yale University School of Medicine
New Haven, Connecticut


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Global Academy for Medical Education. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a web page that will allow you to receive your certificate of credit via e-mail or you may print it out at that time.

System Requirements

PC
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader

MAC
MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Safari
Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Brittany P. Cavanaugh, DO
Nothing to disclose

Neera Dahl, MD
Has been a Consultant/Independent Contractor and a member of the Speakers’ Bureau for Otsuka America Pharmaceutical, Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Tom Garry: Nothing to disclose
Shirley V. Jones, MBA: Nothing to disclose
Mike LoPresti: Nothing to disclose
Ron Schaumburg: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Global Academy for Medical Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Copyright © 2018 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc. and its Licensors. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, the accredited provider or the Publisher will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

Internal Medicine Presentations

0.75 CME
Integrity Continuing Education, Inc.
Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection

Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: November 20, 2018
Expires: November 20, 2019
1 hour to complete

Provided by


Integrity Continuing Education, Inc.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, and otolaryngic allergists involved in the management of patients with severe asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe clinical criteria for severe asthma and outline an approach to assessing symptom control and disease burden
  • Identify known phenotypes of severe asthma
  • Develop an approach to the treatment of severe asthma that is personalized to the individual patient and describe the most recent clinical data on new and emerging therapies for severe asthma
  • Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma

Activity Description

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this initiative is also targeted at providing clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.

Faculty

William W. Busse, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
School of Medicine and Public Health
University of Wisconsin
Madison, Wisconsin


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

William W. Busse, MD
Royalty: Elsevier
Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals, Teva Pharmaceuticals
Data Monitoring Boards/Study Oversight Committees: Boston Scientific, Genentech, ICON Clinical Research Ltd.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of November 20, 2018 through November 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

0.75 CME
American Gastroenterological Association
A Pathway to Evidence-Based Management of IBD

A Pathway to Evidence-Based Management of IBD

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 30, 2018
Expires: October 29, 2019
0.75 hour to complete

Accredited By

The American Gastroenterological Association (AGA) Institute

Target Audience

Gastroenterologists and gastroenterology NPs and PAs

Learning Objectives

  • Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data
  • Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity
  • Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD
  • Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making

Faculty

Gil Y. Melmed, MD, MS
Co-Director, Clinical Inflammatory Bowel Disease
Division of Gastroenterology/Department of Medicine
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure of Conflicts of Interest

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda (Consulting Fees).

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

AGA Institute

  • Monique Dyson, has no affiliations with commercial interests to disclose.
  • Sandra Amos, has no affiliations with commercial interests to disclose.

Physician Continuing Medical Education

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. After the successful completion of A Pathway to Evidence-Based Management of IBD and Optimizing Management in IBD: Challenging Cases, learners will receive an AGA-branded certificate recognizing their mastery of IBD management.



COMPLETE THE EVALUATION FORM AND GET A CHANCE TO WIN A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.
 
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.


Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Salix Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.75 CME
Postgraduate Institute for Medicine
Clinical Conversations: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Clinical Conversations: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: September 25, 2018
Expires: September 24, 2019
45 minutes to complete

Target Audience

US-based dermatology and allergy/immunology clinicians who manage patients with atopic dermatitis (AD)

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  2. Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Faculty

Jonathan I. Silverberg, MD, PhD, MPH (Chair)
Associate Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

Jonathan I. Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, Glenmark, Kiniksa, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Realm, Regeneron-Sanofi, and Roivant (Consulting Fees); Regeneron-Sanofi (Speaker’s Bureau); and Galderma, GlaxoSmithKline, and Regeneron-Sanofi (Contracted Research).


Eric L. Simpson, MD, MCR
Professor of Dermatology, Department of Dermatology
Oregon Health & Science University
Portland, OR

Eric L. Simpson, MD, MCR, has affiliations with AbbVie, Eli Lilly, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Regeneron, and Sanofi Genzyme (Consulting Fees); Eli Lilly, Glaxo Smith Kline, LEO Pharma Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Roivant (Contracted Research).

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

YOUR FEEDBACK IS IMPORTANT!
Complete the Evaluation form for this activity and be entered into a drawing for a $100* Amazon Gift card.

*The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. If you would like to contact RMEI, please email contact@RMEI.com.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

0.50 CME
Vindico
Managing Off Episodes in Patients With Parkinson’s Disease: Unmet Needs and Emerging Options

Managing Off Episodes in Patients With Parkinson’s Disease: Unmet Needs and Emerging Options

Start

Activity Chair

Mark F. Lew, MD, FAAN
Professor of Neurology
Director, Division of Movement Disorders
Vice-Chair, Department of Neurology
VanDerMeulen Chair in PD Research
Keck/USC School of Medicine
Los Angeles, CA

Disclosure: Consulting Fee: Adamas, AbbVie, Acadia, Cynapsus, Lundbeck, Neurocrine, Prexton, Revance, Teva, UCB, US WorldMeds
Speakers Bureau: Acadia, Adamas, Lundbeck, Neurocrine, Teva, UCB
Contracted Research: Acorda, Biotie, Enterin, Michael J. Fox Foundation,NeuroDerm, Parkinson's Study Group, Pharm2B

Faculty

Rajesh Pahwa, MD
Laverne & Joyce Rider Professor of Neurology
Chief, Parkinson & Movement Disorders Division
Director, Parkinson Foundation Center of Excellence
University of Kansas Medical Center
Kansas City, KS

Disclosure: Consulting Fee: Abbott Medical Optics, AbbVie, Acorda, Adamas, Sunovion, US WorldMeds
Speakers Bureau: AbbVie, Acorda, Sunovion
Contracted Research: Abbott Medical Optics, AbbVie, Acorda, Adamas, Bristol-Myers Squibb, Boston Scientific, Cala Health, Cavion, Cynapsus, Intec, Jazz, Kyowa, Lilly, Pfizer, Prexton, Roche, Sunovion, US WorldMeds

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff

Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accredited By

This continuing medical education activity is provided by Vindico Medical Education.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credits
Released: August 30, 2018
Expires: August 30, 2019
0.5 hour to complete

Activity Description

Parkinson's disease is a progressive, chronic, neurodegenerative disorder that affects more than 10 million people worldwide. It is canonically regarded as a hypokinetic motor condition, with bradykinesia, resting tremor, and rigidity as its classic features. However, neuropsychiatric and other nonmotor symptoms can have a greater impact on patients’ quality of life. In early disease, the motor symptoms of many patients can be controlled with the use of levodopa. However, many patients gradually experience “off episodes” in which symptoms re-emerge, often in a severe and long-lasting form. This wearing-off effect of treatment can further reduce quality of life, but treatment options are limited. This CME activity will feature a panel discussion with 2 expert clinicians, who will assess recent therapeutic updates in the treatment of patients with Parkinson’s disease and the latest strategies to manage these off episodes.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the prevalence and burden of off episodes associated with Parkinson's disease
  • Identify patients with Parkinson's disease who are experiencing off episodes and adjust the care plan accordingly
  • Assess the latest clinical advances regarding available and emerging options for the management of off episodes in patients with Parkinson's disease

Target Audience

The intended audience for the activity is neurologists and other health care professionals involved in the treatment of patients with Parkinson's disease.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credits™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
Postgraduate Institute for Medicine
Clinical Convergence®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Clinical Convergence®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: August 30, 2018
Expires: August 29, 2019
45 minutes to complete

Target Audience

US-based dermatology and allergy/immunology clinicians who manage patients with atopic dermatitis (AD)

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  2. Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Faculty

Jonathan I. Silverberg, MD, PhD, MPH (Chair)
Associate Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

Jonathan I. Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, Glenmark, Kiniksa, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Realm, Regeneron-Sanofi, and Roivant (Consulting Fees); Regeneron-Sanofi (Speakers’ Bureau); and Galderma, GlaxoSmithKline, and Regeneron-Sanofi (Contracted Research).


Eric L. Simpson, MD, MCR
Professor of Dermatology, Department of Dermatology
Oregon Health & Science University
Portland, OR

Eric L. Simpson, MD, MCR, has affiliations with AbbVie, Eli Lilly, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Regeneron, and Sanofi Genzyme (Consulting Fees); Eli Lilly, Glaxo Smith Kline, LEO Pharma Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Roivant (Contracted Research).

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

YOUR FEEDBACK IS IMPORTANT!
Complete the Evaluation form for this activity and be entered into a drawing for a $100* Amazon Gift card.

*The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. If you would like to contact RMEI, please email contact@RMEI.com.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

1.00 CME / CNE
AcademicCME
Advancements in the Prevention and Management of Stroke

Advancements in the Prevention and Management of Stroke

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: July 2, 2018
Expires: September 13, 2019
1 hour to complete

Accredited By

Target Audience

Emergency department physicians, neurologists, cardiologists, internists, nurse practitioners, nurses, and other healthcare professionals involved in patient care for prevention and treatment of stroke

Learning Objectives

  • Identify timely assessment strategies to provide the most effective care for patients with stroke
  • Incorporate risk stratification tools into routine clinical practice
  • Explain the latest developments in clinical trials for the treatment and prevention of stroke, including ischemic large hemispheric infarction and stroke-related degeneration
  • Utilize the health care team and shared decision making to achieve improved patient outcomes

Activity Description

This CME/CNE webcast will highlight recent advancements in the prevention and management of stoke. The expert faculty will discuss best practices for assessing risk as well as the modifiable risk factors of stroke. Recent clinical trial data, including that of combination therapy, will be analyzed, as well as strategies for managing the comorbidities that commonly accompany stoke.  Best practices for creating an optimal stroke care team, as outlined by the National Stroke Association, will be reviewed along with models for treatment decision making and implementation. At the conclusion of this discussion-based activity, learners will gain better insight into techniques for optimally treating and managing patients with stroke utilizing a comprehensive, interprofessional approach to care.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with ischemic stroke.

Agenda

  1. Risk Stratification, Prevention and Early Intervention for Patients with Acute Ischemic Stroke
  2. Clinical Trial Update: Data Analysis of Therapeutics for the Prevention and Treatment of Acute Ischemic Stroke
  3. The Importance of Utilizing the Health Care Team and Shared Decision Making to Achieve Improved Patient Outcomes

Faculty

Charles V. Pollack, Jr., MA, MD (Course Chair)
Associate Provost for Innovation in Education
Associate Dean for CME and Strategic Partner Alliances
Department of Emergency Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Director, Jefferson Institute of Emerging Health Professions
Director, The Lambert Center for the Study of Medicinal Cannabis and Hemp
Professor and Senior Advisor for Interdisciplinary Research and Clinical Trials
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania


Rodney D. Bell, MD
Lynne and Harold Honickman Professor of Neurology
Sidney Kimmel Medical School
Thomas Jefferson University
Vice Chairman, Department of Neurology for Hospital Affairs
President of the Medical Staff
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania


John Fanikos, RPh, MBA
Executive Director
Brigham and Women’s Hospital
Clinical Professor
Massachusetts College of Pharmacy
Boston, Massachusetts


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD
Consultant/Advisor: AstraZeneca; Bristol-Myers Squibb; Boehringer Ingelheim; CSL Behring; Janssen Global Services, LLC; Pfizer Inc.; Portola Pharmaceuticals, Inc.
Grant/Research Support: AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo Company, Limited; Janssen Global Services, LLC; Portola Pharmaceuticals, Inc.

Rodney D. Bell, MD
Nothing to disclose.

John Fanikos, RPh, MBA
Consultant/Advisor: Boehringer Ingelheim; Genentech, Inc.; Portola Pharmaceuticals, Inc.

Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or Review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  • All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

Statement of Commercial Support

This activity has been supported by independent educational grants from Biogen and the Bristol-Myers Squibb and Pfizer Alliance.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Biogen and the Bristol-Myers Squibb and Pfizer Alliance do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME
Postgraduate Institute for Medicine
Clinical Reflections®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Clinical Reflections®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 28, 2018
Expires: June 27, 2019
1 hour

Target Audience

US-based dermatology and allergy/immunology clinicians who manage patients with atopic dermatitis (AD)

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Apply current principles of pathophysiology of atopic dermatitis (AD) and the concept of atopic march to therapeutic approaches to disease management
  2. Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  3. Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD
  4. Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Faculty

Jonathan I. Silverberg, MD, PhD, MPH (Chair)
Associate Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

Jonathan I. Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, Glenmark, Kiniksa, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Realm, Regeneron-Sanofi, and Roivant (Consulting Fees); Regeneron-Sanofi (Speakers’ Bureau); and Galderma, GlaxoSmithKline, and Regeneron-Sanofi (Contracted Research).


Emma Guttman, MD, PhD
Professor of Dermatology, Sol and Clara Kest
Icahn School of Medicine at Mount Sinai
New York, NY

Emma Guttman, MD, PhD, has affiliations with AbbVie, Allergan, Almirall, Amgen, Anacor, AnaptyBio, Asana Biosciences, BMS, Celgene, Curadim, Dermira, Drais, Eli Lilly, Escalier, Galderma, Glenmark, Kiowa Kirin, Kymab Limited, Lead Pharma, LEO Pharma Inc., Medimmune, Novartis, Pfizer, Regeneron, Sanofi, Sienna, Stiefel/GlaxoSmithKline, Theravance, and Vitae (Consultant).


Eric Simpson, MD, MCR
Professor of Dermatology, Department of Dermatology
Oregon Health & Science University
Portland, OR

Eric Simpson, MD, MCR, has affiliations with AbbVie, Eli Lilly, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Regeneron, and Sanofi Genzyme (Consulting Fees); Eli Lilly, Glaxo Smith Kline, LEO Pharma Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Roivant (Contracted Research).

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.50 CME / CE
Postgraduate Institute for Medicine
Research-based Clinical Strategies to Prevent and Address Adolescent Substance Use and Prescription Medication Misuse—Being Part of the Solution Part 2

Research-based Clinical Strategies to Prevent and Address Adolescent Substance Use and Prescription Medication Misuse—Being Part of the Solution Part 2

Start

Activity Details

Free
AAFP, ACCME, ANCC, ADA

0.5 Credit

Released: June 29, 2017

Expires: June 27, 2019

30 minutes

No registration required

Target Audience

This activity had been designed to meet the educational needs of clinicians including, physicians, physician assistants, nurse practitioners, nurses, and dentists/oral maxillofacial surgeons, involved in the care of adolescent patients.

Learning Objectives

  • Discuss strategies to address substance use and prescription drug misuse in adolescent patients based on their level of use
  • Summarize when and how to follow up with adolescent patients who use substances or misuse prescription drugs

Activity Description

Videos from your peers enhance this course, which aims to help you navigate confidentiality and confidence in having effective discussions with your teen patients about their substance use. Features tips and talking points for patients at all risk levels, and considerations prescription drug misuse. This course was developed by a Coalition Healthcare Organizations and Providers to help clinicians identify, prevent, and address substance use and prescription medication misuse in their adolescent patients.

Instruction for Claiming Credit

A brief post-test and course evaluation will follow the completion of the course. Please complete these questionnaires to claim credit for this course.

Education Coalition

This activity was developed by an education Coalition of experts and medical professional organization representatives. The Coalition comprises the following organizations and experts:

Type of Reviewer:
Organization/Expert Consultant
Reviewer Name
California Academy of Family Physicians (CAFP) Cynthia Kear, Senior Vice President
American Society of Addiction Medicine (ASAM) Jennifer Butchart, Education Coordinator
Penny Mills, Executive Vice President / CEO
Arlene Deverman, VP Professional Development
American Osteopathic Association (AOA)

Stephanie Townsell, Director, Public Health
Marla Kushner, DO

American Association of Nurse Practitioners (AANP) Anne Norman, DNP, APRN, FNP-C, FAANP Vice President of Education and Accreditation
American Academy of Pediatrics (AAP) Renee Jarrett, Manager, Mental Health and Foster Care Initiatives
Div of Developmental Pediatrics and Preventive Services
American Academy of Physician Assistants (AAPA) Daniel Pace, Vice President, Education
Marie-Michele Leger, MPH, PA-C, Director, Clinical Education
Sara Evans, PMP, Project Manager, Quality Improvement Initiatives
American Association of Oral and Maxillofacial Surgeons (AAOMS) Vincent DiFabio, DDS
Consultant Samantha Mattiucci, PharmD, Director of Medical Education
Consultant Jan Schultz, BSN, MSN, RN, CCMEP, Director of Education Outcomes and Accreditation Services
Consultant Dan Alford, MD, Associate Professor of Medicine, Assistant Dean and Program Director of the Addiction Medicine Residency program at Boston University School of Medicine
Consultant Sharon Levy, MD, MPH, FAAP, Director, Adolescent Substance Abuse Program (ASAP) Assistant Professor in Pediatrics, Boston Children's Hospital
Consultant Jeff Baxter, MD, Assistant Professor
Department of Family Medicine and Community Health, University of Massachusetts Medical School
Consultant Marc Fishman, MD
Consultant Carol Havens, MD

Conflict of Interest Policy/ Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The Education Coalition members reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Marc Fishman, MD discloses the following: Consulting Fees: US World Meds; Contracted Research: Media Rez, US World Meds; Ownership Interest: Maryland Treatment Centers

The following Education Coalition members have nothing to disclose: Cynthia Kear, Jennifer Butchart, Penny Mills, Arlene Deverman, Stephanie Townsell, Marla Kushner, Anne Norman, Renee Jarrett, Daniel Pace, Marie-Michele Leger, Sara Evans, Vincent DiFabio, Jan Schultz, Dan Alford, Sharon Levy, Jeff Baxter, Marc Fishman, and Carol Havens

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following National Institute on Drug Abuse planners and managers, Elisabeth Davis; Carol Krause; Josie Anderson; Jack Stein, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

 The following JBS International, Inc. planners and managers, Candace Baker; Susan Hayashi; Laura Nolan; Bethel Arya; and Veronica Junghahn, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and the National Institute for Drug Abuse. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/30/2017. Term of approval is for one year from this date.

This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.00 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.

Nursing Continuing Education

Credit Designation
This educational activity for 0.5 contact hour is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Accreditation Council for Pharmacy EducationPostgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.


American Dental Association CERP Recognition

This continuing education activity has been planned and implemented in accordance with the standards of the ADA Continuing Education Recognition Program (ADA CERP) through joint sponsorship efforts between Postgraduate Institute for Medicine and the National Institute for Drug Abuse.

Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry.

Postgraduate Institute for Medicine designates this activity for 0.5 continuing education credit.

Statement of Commercial Support

There is no commercial funding for this activity.

Media

Internet activity

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware / Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CE
Postgraduate Institute for Medicine
Research-based Clinical Strategies to Prevent and Address Adolescent Substance Use and Prescription Medication Misuse—Being Part of the Solution Part 1

Research-based Clinical Strategies to Prevent and Address Adolescent Substance Use and Prescription Medication Misuse—Being Part of the Solution Part 1

Start

Activity Details

Free
AAFP, ACCME, ANCC, ADA

0.5 Credit

Released: June 29, 2017

Expires: June 27, 2019

30 minutes

No registration required

Target Audience

This activity had been designed to meet the educational needs of clinicians including, physicians, physician assistants, nurse practitioners, nurses, and dentists/oral maxillofacial surgeons, involved in the care of adolescent patients.

Learning Objectives

  • Describe the prevalence of substance use and prescription medication misuse among adolescents
  • Explain why adolescents are at high risk of developing a substance use disorder, and how clinicians can help to prevent it
  • Demonstrate strategies to build trust with adolescent patients, and ensure confidentiality when addressing substance use and prescription medication misuse

Activity Description

Videos from your peers enhance this course, which aims to help you navigate confidentiality and confidence in having effective discussions with your teen patients about their substance use. Features tips and talking points for patients at all risk levels, and considerations of prescription drug misuse. This course was developed by the Coalition of Healthcare Organizations and Providers to help clinicians identify, prevent, and address substance use and prescription medication misuse in their adolescent patients.

Instruction for Claiming Credit

A brief post-test and course evaluation will follow the completion of the course. Please complete these questionnaires to claim credit for this course.

Education Coalition

This activity was developed by an education Coalition of experts and medical professional organization representatives. The Coalition comprises the following organizations and experts:

Type of Reviewer:
Organization/Expert Consultant
Reviewer Name
California Academy of Family Physicians (CAFP) Cynthia Kear, Senior Vice President
American Society of Addiction Medicine (ASAM) Jennifer Butchart, Education Coordinator
Penny Mills, Executive Vice President / CEO
Arlene Deverman, VP Professional Development
American Osteopathic Association (AOA)

Stephanie Townsell, Director, Public Health
Marla Kushner, DO

American Association of Nurse Practitioners (AANP) Anne Norman, DNP, APRN, FNP-C, FAANP Vice President of Education and Accreditation
American Academy of Pediatrics (AAP) Renee Jarrett, Manager, Mental Health and Foster Care Initiatives
Div of Developmental Pediatrics and Preventive Services
American Academy of Physician Assistants (AAPA) Daniel Pace, Vice President, Education
Marie-Michele Leger, MPH, PA-C, Director, Clinical Education
Sara Evans, PMP, Project Manager, Quality Improvement Initiatives
American Association of Oral and Maxillofacial Surgeons (AAOMS) Vincent DiFabio, DDS
Consultant Samantha Mattiucci, PharmD, Director of Medical Education
Consultant Jan Schultz, BSN, MSN, RN, CCMEP, Director of Education Outcomes and Accreditation Services
Consultant Dan Alford, MD, Associate Professor of Medicine, Assistant Dean and Program Director of the Addiction Medicine Residency program at Boston University School of Medicine
Consultant Sharon Levy, MD, MPH, FAAP, Director, Adolescent Substance Abuse Program (ASAP) Assistant Professor in Pediatrics, Boston Children's Hospital
Consultant Jeff Baxter, MD, Assistant Professor
Department of Family Medicine and Community Health, University of Massachusetts Medical School
Consultant Marc Fishman, MD
Consultant Carol Havens, MD

Conflict of Interest Policy/ Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The Education Coalition members reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Marc Fishman, MD discloses the following: Consulting Fees: US World Meds; Contracted Research: Media Rez, US World Meds; Ownership Interest: Maryland Treatment Centers

The following Education Coalition members have nothing to disclose: Cynthia Kear, Jennifer Butchart, Penny Mills, Arlene Deverman, Stephanie Townsell, Marla Kushner, Anne Norman, Renee Jarrett, Daniel Pace, Marie-Michele Leger, Sara Evans, Vincent DiFabio, Jan Schultz, Dan Alford, Sharon Levy, Jeff Baxter, Marc Fishman, and Carol Havens

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following National Institute on Drug Abuse planners and managers, Elisabeth Davis; Carol Krause; Josie Anderson; Jack Stein, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

 The following JBS International, Inc. planners and managers, Candace Baker; Susan Hayashi; Laura Nolan; Bethel Arya; and Veronica Junghahn, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and the National Institute for Drug Abuse. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/30/2017. Term of approval is for one year from this date.

This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.00 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.

Nursing Continuing Education

Credit Designation
This educational activity for 0.5 contact hour is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Accreditation Council for Pharmacy EducationPostgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.


American Dental Association CERP Recognition

This continuing education activity has been planned and implemented in accordance with the standards of the ADA Continuing Education Recognition Program (ADA CERP) through joint sponsorship efforts between Postgraduate Institute for Medicine and the National Institute for Drug Abuse.

Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry.

Postgraduate Institute for Medicine designates this activity for 0.5 continuing education credit.

Statement of Commercial Support

There is no commercial funding for this activity.

Media

Internet activity

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware / Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pages